{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:43:05Z","timestamp":1760784185652},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,4,16]],"date-time":"2003-04-16T00:00:00Z","timestamp":1050451200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1007\/s00228-003-0579-1","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T13:41:45Z","timestamp":1478958105000},"page":"169-175","source":"Crossref","is-referenced-by-count":16,"title":["Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits"],"prefix":"10.1007","volume":"59","author":[{"given":"Jorge","family":"Gomez Cerezo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubin","family":"Lubomirov Hristov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio J.","family":"Carcas Sansu\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"V\u00e1zquez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,4,16]]},"reference":[{"key":"0579_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0002-9343(98)00072-2","volume":"105","author":"Singh","year":"1998","unstructured":"Singh G (1998) Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105(1B):31\u201338","journal-title":"Am J Med"},{"key":"0579_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0002-9343(98)00274-5","volume":"105","author":"McCarthy","year":"1998","unstructured":"McCarthy D (1998) Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 105(5A):3\u20139","journal-title":"Am J Med"},{"key":"0579_CR3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/gast.2001.21907","volume":"120","author":"Laine","year":"2001","unstructured":"Laine L (2001) Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120:594\u2013606","journal-title":"Gastroenterology"},{"key":"0579_CR4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","volume":"123","author":"Silverstein","year":"1995","unstructured":"Silverstein FE, Graham DY, Senior JR et al. (1995) Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123:241\u2013249","journal-title":"Ann Intern Med"},{"key":"0579_CR5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247\u20131255","journal-title":"JAMA"},{"key":"0579_CR6","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520\u20131528","journal-title":"N Engl J Med"},{"key":"0579_CR7","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","volume":"95","author":"Goldstein","year":"2000","unstructured":"Goldstein JL, Silverstein FE, Agrawal NM et al. (2000) Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 95:1681\u20131690","journal-title":"Am J Gastroenterol"},{"key":"0579_CR8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","volume":"282","author":"Langman","year":"1999","unstructured":"Langman MJ, Jensen DM, Watson DJ et al. (1999) Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282:1929\u20131933","journal-title":"JAMA"},{"key":"0579_CR9","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0002-9270(01)02303-6","volume":"96","author":"Goldstein","year":"2001","unstructured":"Goldstein JL, Correa P, Zhao WW et al. (2001) Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared with naproxen in patients with arthritis. Am J Gastroenterol 96:1019\u20131027","journal-title":"Am J Gastroenterol"},{"key":"0579_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","volume":"43","author":"Hawkey","year":"2000","unstructured":"Hawkey C, Laine L, Simon T et al. (2000) Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 43:370\u2013377","journal-title":"Arthritis Rheum"},{"key":"0579_CR11","unstructured":"FDA Advisory Committee (2000). Celecoxib Medical Officer's Gastroenterology Review (CLASS Study). http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b1_05_gi.pdf"},{"key":"0579_CR12","unstructured":"FDA Advisory Committee (2000). Celecoxib Statistical Review (CLASS study). http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b1_04_stats.pdf"},{"key":"0579_CR13","unstructured":"FDA Advisory Committee (2000). Rofecoxib Statistical Review (VIGOR study). http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b2_04_stats.pdf"},{"key":"0579_CR14","unstructured":"FDA Advisory Committee (2000). Celecoxib Medical Officer Review (CLASS study). http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3677b1_03_med.pdf"},{"key":"0579_CR15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0016-5085(08)80516-1","volume":"120","author":"Goldstein","year":"2001","unstructured":"Goldstein JL, Eisen GM, Stenson W et al. (2001) Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs. The SUCCESS I Trial (abstract). Gastroenterology 120:105","journal-title":"Gastroenterology"},{"key":"0579_CR16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bmj.325.7373.S163","volume":"325","author":"J\u00c3\u00bcni","year":"2002","unstructured":"J\u00fcni P, Rutjes AW, Dieppe PA (2002) Pharmacia addresses June 1 editorial regarding CLASS study: authors' response. BMJ 325:163\u2013164","journal-title":"BMJ"},{"key":"0579_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/bmj.325.7356.161","volume":"325","author":"Geis","year":"2002","unstructured":"Geis GS (2002) Are selective COX-2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial. BMJ 325:161\u2013162","journal-title":"BMJ"},{"key":"0579_CR18","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/bmj.324.7349.1287","volume":"324","author":"J\u00c3\u00bcni","year":"2002","unstructured":"J\u00fcni P, Rutjes AWS, Dieppe PA (2002) Are selective COX-2 inhibitors superior to traditional nonsteroidal anti-inflammatory drugs? (editorial) BMJ 324:1287\u20131288","journal-title":"BMJ"},{"key":"0579_CR19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","volume":"325","author":"Deeks","year":"2002","unstructured":"Deeks JJ, Smith LA, Bradley MD (2002) Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. BMJ 325:619\u2013623","journal-title":"BMJ"},{"key":"0579_CR20","doi-asserted-by":"crossref","unstructured":"Wright JM (2002) A missed opportunity (electronic response to: Deeks et al. 2002 Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. BMJ 325:619\u2013623) BMJ http:\/\/bmj.com\/cgi\/eletters\/325\/7365\/619#26374 (accessed 22 November 2002)","DOI":"10.1136\/bmj.325.7365.619"},{"key":"0579_CR21","doi-asserted-by":"crossref","unstructured":"J\u00fcni P, Sterchi R, Dieppe PA (2002) Problems compromising the review's validity. (electronic response to: Deeks et al. 2002 Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. BMJ 325:619\u2013623) BMJ http:\/\/bmj.com\/cgi\/eletters\/325\/7365\/619#26374 (accessed 22 November 2002)","DOI":"10.1136\/bmj.325.7365.619"},{"key":"0579_CR22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/bmj.325.7365.607","volume":"325","author":"Jones","year":"2002","unstructured":"Jones R (2002) Efficacy and safety of COX-2 inhibitors. New data are encouraging but the risk-benefit ratio remains unclear (editorial). BMJ 325:607\u2013608","journal-title":"BMJ"},{"key":"0579_CR23","first-page":"1131","volume":"167","author":"Wright","year":"2002","unstructured":"Wright JM (2002) The double-edged sword of COX-2 selective NSAIDs. CMAJ 167:1131\u20131137","journal-title":"CMAJ"},{"key":"0579_CR24","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(94)92407-4","volume":"343","author":"Bobbio","year":"1994","unstructured":"Bobbio M, Demichelis B, Giustetto G (1994) Completeness of reporting trials results: effect on physicians' willingness to prescribe. Lancet 343:1209\u20131211","journal-title":"Lancet"},{"key":"0579_CR25","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/bmj.312.7034.846a","volume":"312","author":"Shield","year":"1996","unstructured":"Shield MJ, Morant SV (1996) Misoprostol in patients taking nonsteroidal anti-inflammatory drugs (letter). BMJ 312:846","journal-title":"BMJ"},{"key":"0579_CR26","first-page":"1125","volume":"167","author":"Mamdani","year":"2002","unstructured":"Mamdani M, Rochon P, Laupacis A, Anderson G (2002) Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. CMAJ 167:1125\u20131126","journal-title":"CMAJ"},{"key":"0579_CR27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.325.7365.624","volume":"325","author":"Mamdani","year":"2002","unstructured":"Mamdani M, Rochon PA, Juurlink DN et al. (2002) Observational study of upper gastrointestinal hemorrhage in elderly patients given selective cyclooxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs. BMJ 325:624\u2013629","journal-title":"BMJ"},{"key":"0579_CR28","unstructured":"Villa LF (ed) (2001) Medimecum: gu\u00eda de terapia farmacol\u00f3gica, 6th edn. Adis, Madrid"},{"key":"0579_CR29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJM200103293441304","volume":"344","author":"Chan","year":"2001","unstructured":"Chan FKL, Chung SCS, Suen BY et al. (2001) Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344:967\u2013973","journal-title":"N Engl J Med"},{"key":"0579_CR30","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/00019053-200119100-00005","volume":"19","author":"Marshall","year":"2001","unstructured":"Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA (2001) Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs on osteoarthritis. Pharmacoeconomics 19:1039\u20131049","journal-title":"Pharmacoeconomics"},{"key":"0579_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3111\/200104001017","volume":"4","author":"Moore,","year":"2001","unstructured":"Moore, RA, Phillips CJ, Pellissier JM, Kong SX (2001) Health economics comparisons of rofecoxib versus conventional nonsteroidal anti-inflammatory drugs for osteoarthritis in the United Kingdom. J Med Econ 4:1\u20137","journal-title":"J Med Econ"},{"key":"0579_CR32","first-page":"33","volume":"1","author":"Burke","year":"2001","unstructured":"Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL (2001) A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics (Suppl 1) 19:33\u201347","journal-title":"Suppl"},{"key":"0579_CR33","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.282.20.1961","volume":"282","author":"Peterson","year":"1999","unstructured":"Peterson WL, Cryer B (1999) COX-1-Sparing NSAIDs Is the enthusiasm justified? (editorial) JAMA 282:1961-1963","journal-title":"JAMA"},{"key":"0579_CR34","unstructured":"Mayordomo J (2002) Sanidad extiende a toda Espa\u00f1a un modelo andaluz de control de recetas: La medida se aplicar\u00e1 a los antiinflamatorios Vioxx y Celebrex. El Pa\u00eds 19 June, p 42"},{"key":"0579_CR35","unstructured":"Direcci\u00f3n General de Farmacia y Productos Sanitarios (DGFPS) (2002) Resoluci\u00f3n que establece la necesidad de visado de inspecci\u00f3n previo a su dispensaci\u00f3n con cargo al Sistema Nacional de Salud para las especialidades de Celebrex y Vioxx. Ministrerio de Sanidad y Consumo. 17 June 2002"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-003-0579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-003-0579-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-003-0579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-003-0579-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T10:42:10Z","timestamp":1568544130000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-003-0579-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,16]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["0579"],"URL":"https:\/\/doi.org\/10.1007\/s00228-003-0579-1","relation":{},"ISSN":["0031-6970"],"issn-type":[{"value":"0031-6970","type":"print"}],"subject":[],"published":{"date-parts":[[2003,4,16]]}}}